Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Midodrine vs Desmopressin for Weaning IV Noradrenaline in Spinal Shock
NCT04586790Phase 2Unknown
- Start
- Oct 2020
- Primary completion
- Jan 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of midodrine and desmopressin in spinal shock (3 arms). Primary endpoint: liberation the patient from IV vasopressors with maintaining hemodynamics at 48 hours. Status: unknown.
02
Drugs
midodrinedesmopressin
03
Conditions
spinal shock
Beyond the preview
Go deeper on NCT04586790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04586790.